SCHEDULE: Janus Henderson Discloses 9.99% Stake in Benitec Biopharma

Janus Henderson Group plc and its affiliate have filed an amended Schedule 13G, disclosing a beneficial ownership of 9.99% in Benitec Biopharma Inc. common stock.

Summary

• Janus Henderson Group plc, a Jersey-based holding company and investment adviser, has filed an Amendment No. 10 to Schedule 13G regarding its ownership in Benitec Biopharma Inc.
• The filing indicates that Janus Henderson Group plc beneficially owns 3,382,836 shares of Benitec Biopharma Inc. common stock, representing 9.99% of the class.
• This ownership includes certain pre-funded and/or common warrants, which are only exercisable to the extent that the holders would not beneficially own more than 9.99% of the outstanding common stock.
• An additional 3,283,108 pre-funded and 1,642,586 common warrants are not reflected in the reported figures due to this 9.99% ownership limitation.
• Janus Henderson Biotech Innovation Master Fund Ltd, a Massachusetts-based investment company and an indirect subsidiary of Janus Henderson Group plc, beneficially owns 2,067,781 shares, representing 6.1% of the class.
• Both reporting persons hold shared voting and shared dispositive power over their respective beneficially owned shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Benitec Biopharma Inc.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that inherently indicates a positive or negative sentiment regarding the issuer's performance or outlook. The presence of a significant institutional investor can be viewed as a neutral to slightly positive signal.

Positives

• Significant institutional investment by Janus Henderson Group plc, a major asset manager, may signal confidence in Benitec Biopharma Inc.'s long-term prospects.
• The substantial 9.99% stake indicates a notable commitment from a reputable investment firm, potentially attracting further investor interest.

Negatives

• The 9.99% beneficial ownership limitation on warrant exercise restricts Janus Henderson's ability to immediately convert all potential shares if it would exceed this regulatory threshold, potentially limiting their flexibility to increase their stake without triggering a more detailed 13D filing.

Risks

• The beneficial ownership is capped at 9.99% due to regulatory limitations on warrant exercise, meaning a significant portion of potential shares from warrants (3,283,108 pre-funded and 1,642,586 common warrants) are not currently reflected in the reported ownership.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Benitec Biopharma Inc.'s future performance or strategic direction. It solely reports current beneficial ownership by Janus Henderson Group plc.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Signed by Kristin Mariani, Head of North America Compliance, CCO for both reporting persons)

Industry Context

This filing reflects a common practice in the biotechnology sector where institutional investors like Janus Henderson acquire significant stakes in emerging biopharma companies. Such investments can provide capital stability and market validation, often preceding or accompanying key clinical milestones or commercialization efforts. The focus on biotech innovation aligns with broader industry trends of investment in novel therapeutic platforms.

Comparison to Industry Standards

• Institutional ownership disclosures via Schedule 13G are standard practice for investors holding between 5% and 20% of a company's stock, indicating a passive investment intent.
• The 9.99% ownership threshold is a common strategy for institutional investors to maintain a significant stake without triggering the more stringent reporting requirements and control implications of a Schedule 13D filing.
• Many biotech companies, particularly those in clinical development stages like Benitec Biopharma, rely heavily on institutional investment for funding and market liquidity, making such disclosures a routine part of their investor relations landscape.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like Janus Henderson may enhance market confidence and potentially influence the stock's perception among other investors.
• Company Management: Increased institutional ownership often brings greater scrutiny and engagement from large investors, potentially influencing strategic decisions or corporate governance.

Next Steps

• Janus Henderson Group plc will continue to monitor its investment in Benitec Biopharma Inc. and may file further amendments to Schedule 13G or a Schedule 13D if its investment intent or ownership percentage changes significantly.

Key Dates

Keywords

Benitec Biopharma Inc., Janus Henderson Group plc, Schedule 13G, Institutional Ownership, Common Stock, Biopharma, Investment Adviser, Warrants, SEC Filing